RENUKA BISWAS_042411110084

NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

AGE/GENDER :62 Y/Female INVOICE DATE :11/Nov/2024 12:02PM
TESTREQUEST ID :042411110084 SPECIMEN COLLECTED :11/Nov/2024 01:45PM
REFERRED BY :Dr. Santosh Kumar REPORT DATE :11/Nov/2024 05:37PM
Test Name Result Bio.Ref.Int. Unit Method
BIOCHEMISTRY
Primary Sample Type:Fluoride Plasma-R
Glucose Random 80 70-140 mg/dL Hexokinase
Primary Sample Type:Serum
Urea 25 21-43 mg/dl GLDH-Urease
Creatinine 0.89 < 1.12 mg/dl Enzymatic
SGPT (ALT) 38 < 28 U/L IFCC
SGOT (AST) 25 ≤ 32 U/L IFCC
Sodium 129 136 - 145 mmol/L ISE(Indirect)
N.B : Please correlate clinically.
Potassium 5.2 3.5 - 5.1 mmol/L ISE(Indirect)
N. B : Please correlate clinically.
Equipment Used:Cobas_6000
Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 1 of

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

HAEMATOLOGY
CBC/COMPLETE HAEMOGRAM
Primary Sample Type:EDTA Blood
Haemoglobin 10.3 12-15 gm/dl Non Cyanmeth Hb/SLS
Colorimetric
Total count
Erythrocytic 3.95 3.8-4.8 mil/cu.mm DC detection
Leucocytic 7560 4000-10000 /cu.mm Fluorescent flow
cytometry
Differential leucocyte count
Neutrophil 66.0 40-80 % Fluorescent flow
cytometry/Microscopy
Lymphocytes 24.6 20-40 % Fluorescent flow
Monocytes 6.3 02-10 % Fluorescent flow
Eosinophils 2.8 01-06 % Fluorescent flow
Basophils 0.3 0-2 % Fluorescent flow
Absolute Leucocyte Count
Neutrophil. 4,990 2000-7000 /cu.m Fluorescent flow
cytometry
Lymphocyte. 1,860 1000-3000 /cu.m Fluorescent flow
cytometry
Monocyte. 480 200-1000 /cu.m Fluorescent flow
cytometry
Eosinophil. 210 20-500 /cu.m Fluorescent flow
cytometry
Basophil. 20 20-100 /cu.m Fluorescent flow
cytometry
Equipment Used:XN1000

Standard 13
NAME :Ms. RENUKA BISWAS

Platelet count 1.84 1.5-4.1 lakhs/cu.mm DC
detection/Microscopy
ESR 1st Hour 48 <35 mm/1st hr Modified Westergren
PCV 33.4 36-46 % Cumulative pulse height
detection
MCV 84.6 83-101 fL Calculated
MCH 26.1 27-32 pg Calculated
MCHC 30.8 31.5-34.5 % Calculated
Rdw-cv 15.5 11.4-14.0 % Calculated
Equipment Used:XN1000

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

HAEMATOLOGY
BLOOD GROUP RH TYPE
ABO B Forward and Reverse
grouping (Slide & Tube)
Rh typing Positive
NOTE :
* Apart from major A,B,H antigens which are used for ABO grouping and Rh typing, many minor blood group
antigens exist. Agglutination may also vary according to titre of antigen and antibody.
* So before transfusion, reconfirmation of blood group as well as cross-matching is needed.
* Presence of maternal antibodies in newborns, may interfere with blood grouping.
* Auto agglutination (due to cold antibody, falciparum malaria, sepsis, internal malignancy etc.) may also cause
erroneous result.

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

HAEMATOLOGY
PROTHROMBIN TIME (P-TIME)
Primary Sample Type:SODIUM CITRATE
Prothrombin Time (P Time) 10.30 11-16 Sec.
MNPT (Control) 10.60 Sec Optical
turbodensitometry
Ratio(Test:Mnpt) 0.97
International normalized ratio (INR) 0.97 (0.8--1.2: for patient not on anticoagulants)
(2.0-3.0:for patients on anticoagulants)
(2.5-3.5: for patients with mechanical heart valve)
Equipment Used: Coagulometer (CA-104)

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

HAEMATOLOGY
GLYCOSYLATED HAEMOGLOBIN (HBA1C)
Primary Sample Type:EDTA Blood
Glycosylated Hemoglobin (HbA1c) 5.40 % HPLC
Non diabetic/Excellent control : 4 – 6 %

Good control : 6-7 %
Unsatisfactory control : 7-8 %
Poor control : >8 %
According to ADA (AMERICAN DIABETIC ASSOCIATION): Prediabetes HbA1c : 5.7%-6.4%

Diabetes HbA1c : ≥ 6.5%
Assay done by : Bio-Rad : D-10 (HPLC) / VARIANT II TURBO
ADA criteria for correlation between HbA1c & Mean plasma glucose levels:
(Last three month's average).
HbA1c (%) Mean Plasma Glucose (mg / dl)
6 126
7 154
8 183
9 212
10 240
11 269
12 298
Factors that Interfere with HbA1c Measurement : Genetic variants (e.g. HbS trait), elevated fetal hemoglobin (HbF)
and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy
of HbA1c measurements. The effects vary depending on the specific Hb variant or derivative and the specific HbA1c method.
Factors that affect Interpretation of HbA1c Results : Any condition that shortens erythrocyte survival or decreased mean

Standard 13
erythrocyte are (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results regardless of the
asaay method used.
1. Erythropoiesis :: Increased hbA1c : Iron, Vitamin B12 deficiency, decreased erythropoietin.

Decreased HbA1c : Administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic Liver disease.
2. Altered Haemoglobin :: Genetic or chemical alterations in haemoglobin : Haemoglobinopathies, HbF,
methaemoglobin, may increase or decrease HbA1c.
3. Glycation :: Increased HbA1c : Alcoholism, chronic renal failure, decreased intraerythrocyte pH.
Decreased HbA1c : Aspirin, vitamin C and E, certain Haemoglobinopathies, increased intraerythrocyte pH.
Variable HbA1c : Genetic determinants.
4. Erythrocyte destruction :: Increased HbA1c : Increased erythrocyte life span : Splenectomy.
Decreased A1c : Decreased erythrocyte life span : haemoglobinopathies, splenomegaly, rheumatoid arthritis or
drugs such as antiretrovirals, ribavirin and dapsone.
5. Assays :: Increased HbA1c : Hyperbilirubinaemia, carbamylated haemoglobin, alcoholism, large dose of Aspirin,
chronic opiate use.
Variable HbA1c : Haemoglobinopathies.
Decreased HbA1c : Hypertriglyceridaemia.
6. Falsely Low HbA1c : Dapsone, Ribavirin, Antiretrovirals, Trimethoprim-Sulfamethoxazole, Hydroxyurea, Vitamin C,
Vitamin E, Aspirin (small doses).
Falsely High HbA1c : Aspirin (large doses) Chronic opiate use.

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

CLINICAL PATHOLOGY
URINE RE
Primary Sample Type:Urine
Physical examination
Quantity 40 mL
Colour Watery
Appearance Clear Clear
Deposits Nil
Sp.gravity 1.005 1.003-1.030 Ions concentration
Chemical examination
Reaction Acidic Double indicator pH
range
Urine protein Nil Nil Protein Error Indicator
Urine Sugar Nil Nil GOD POD Reaction
Ketones Nil Nil Nitroprusside
Bile salt. Negative Negative Hays Sulphur Test
Bile pigment. Negative Negative Diazo Reaction
Urobilinogen Normal upto 1.0 mg/dl mg/dl Ehrlich Reaction
Phosphates. Nil Nil Heat and Acetic Acid
Blood Nil Nil Peroxidase
Nitrite Negative NEGATIVE P-Arsalinic Acid
Leucocyte Nil Esterase
Microscopical Examination of Centrifuged Deposit
RBC. Nil - /HPF Microscopy
Epithelial cells 2-3 (squamous) Occasional /HPF Microscopy
Pus cells. 1-2 0-4 /HPF Microscopy
Casts Nil Occasional /LPF Microscopy
Crystals Nil - /LPF Microscopy
Micro Organism Nil Microscopy
Yeast cells Nil - Microscopy

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

ENDOCRINOLOGY
T4 + TSH
Primary Sample Type:Serum
Serum T4 7.10 5.10-14.1 µg/dl ECLIA
TSH 0.903 0.27-4.20 µIU/ml ECLIA
(Pregnancy :
1st Trimester:0.1-2.5
2nd Trimester:0.2-3.0
3rd Trimester:0.3-3.0)
NOTE:
1. Biotin containing medications can interfare with results. There should be a gap of atleast eight hours between
biotin intake and giving blood sample.
2.TSH levels are subject to circadian variation, reaching peak levels between 2-4 am and at a minimum
between 6-10 pm.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH
concentrations.
3.Subclinical hypothyroidism is diagnosed when you have:
• No symptoms or mild symptoms of hypothyroidism. ( Like fatigue, cold intolerance, consistent weight
gain, depression or memory problems).
• A mildly high thyroid-stimulating hormone (TSH) level.
• A normal thyroxine (T4) level.
• A TSH level < 10 µIU/mL may be followed up by re-estimation after 4-8 weeks before starting treatment.
• Viral infection, common cold etc. May cause transient increase in TSH for few days, which will revert to
normal after the illness passes away.
4. Values < 0.03 µlU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals.
Equipment Used:Cobas_6000

Standard 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

SEROLOGY
HIV I & II
HIV - I & II 0.09 CMIA
Kit Used : ARCHITECT HIV Ag/Ab Combo Reagent Kit.
Interpretation of Results :
. Specimens with S/CO values < 1.00 are considered Non-Reactive (NR).
. Specimens with S/CO values ≥ 1.00 are considered Reactive (R)
Limitations Of The Procedure :
1. This is only a screening test confirmatory testing by other methods is necessary for diagnosis.
2. Definitive clinical diagnosis should not be made based only on the result of single test. A complete evaluation
by physician is needed for a final diagnosis.
3. Specimens from patients who have received preparations of mouse monocional antibodies for diagnosis or
therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely
elevated or depressed values when tested with assay kits that employ mouse monocional antibodies.
ARCHITECT HIV Ag/Ab Combo reagents contain a component that reduces the effect of HAMA reactive
specimens. Additional clinical or diagnostic information may be required to determine patient status.
4. Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro
immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this
interference and anomalous values may be observed. Additional information may be required for diagnosis.
Equipment Used:Architect_ci4100
Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 10

Standard of 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

SEROLOGY
HCV CARD TEST
Anti-HCV ANTIBODY DETECTION Non-Reactive Immunochromatography
Note : i. The HCV Tri-Dot HCV test detects anti-HCV in human serum or plasma and is only a screening
test. All reactive samples should be confirmed by supplemental assays like RIBA, PCR. Therefore for a definitive
diagnosis, the patient's clinical history, symptomatology as well as serological data, should be considered.
ii. A non-reactive result does not exclude the possibility of exposure to or infection with HCV.
iii. The presence of anti-HCV does not imply a Hepatitis C infection but may be indicative of recent and /or
past infection by HCV.
iv. Patients with auto-immune liver disease may show falsely reactive results

Standard of 13
NAME
THEISM DIAGNOSTICS
:Ms. RENUKA BISWAS

SEROLOGY
HbsAg 0.27 S/CO ≥ 1.0 = Reactive S/CO
S/CO < 1.0 = Non-reactive
Method : CMIA
Note:
HBsAg usually appears 4 weeks after viral exposure but can be detected any time after the first week. An individual positive for
HBsAg is considered to be infected and is therefore potentially infectious. Persistence of HBsAg is used to differentiate acute from
chronic infection. Presence of the antigen longer than 6 months after initial exposure indicates chronic infection. However, the level
of the antigen does not appear to correlate with disease severity. HBsAg can be cleared by normal immune response, and only
1% of patients with acute HBV exposure are estimated to progress to a chronic state. Detection of anti-HBs in the serum implies
either active or passive immunization that usually persists for life.
Anti-HBc is the first detectable antibody in the course of HBV disease. IgM anti-HBc indicates acute infection and is the only
serologic marker detectable during the “Window period,” when neither HBsAg nor anti-HBc is detectable. Once IgG anti HBc
appears in the serum, it persists for life. Detection of IgG anti-HBc indicates previous or ongoing infection.
Individuals with positive HbeAg results have been shown to have higher rates or viral transmission; therefore, the antigen is used as
a marker of viral replication and infectivity. However, HbeAg testing is indicated primarily during follow-up of chronic infection
rather than acute infection because of its variable level during the acute phase.
Equipment Used:Architect_ci4100

Standard of 13
THEISM DIAGNOSTICS

MICROBIOLOGY
CULTURE AND SENSITIVITY (AEROBIC)
Primary Sample Type : Urine
Routine Culture : Aerobic: No significant microorganism grown after 48 hours

of aerobic incubation at 37ºC.
*** End Of Report ***

Standard of 13
THEISM ULTRASOUND CENTRE PATIENT REPORT
BIO-RAD VARIANTII TURBO S/N: 16549 V2TURBO_A1c_2.0
Patient Data Analysis Data

Sample ID: 21199001 Analysis Performed: 11/11/2024 16:03:05
Patient ID: 084 Injection Number: 3496U
Name: Run Number: 138
Physician: Rack ID: 0003
Sex: Tube Number: 3
DOB: Report Generated: 11/11/2024 16:08:44
Operator ID:
Comments:
NGSP Retention Peak

Peak Name % Area % Time (min) Area
A1a --- 1.1 0.162 26190
A1b --- 0.9 0.233 22457
F --- 0.6 0.280 14660
LA1c --- 1.5 0.416 35720
A1c 5.4 --- 0.527 109237
P3 --- 3.6 0.813 86336
P4 --- 1.2 0.881 29931
Ao --- 86.5 1.002 2084895
Total Area: 2,409,426
HbA1c (NGSP) = 5.4 %
20.0
17.5
15.0
12.5
%A1c
10.0
0.53
0.81
7.5
A1c -
0.88
-
0.23
0.42
5.0
0.16
0.28
-
-
2.5
1.00
-
0.0
-
0.00 0.25 0.50 0.75 1.00 1.25 1.50

Time (min.)

RENUKA BISWAS_042411110084

Uploaded by

Copyright:

Available Formats

RENUKA BISWAS_042411110084

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

RENUKA BISWAS_042411110084

Uploaded by

Copyright:

Available Formats

NAME

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 1 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 2 of

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 3 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 4 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Equipment Used: Coagulometer (CA-104)

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 5 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Non diabetic/Excellent control : 4 – 6 %

According to ADA (AMERICAN DIABETIC ASSOCIATION): Prediabetes HbA1c : 5.7%-6.4%

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 6 of

Test Name Result Bio.Ref.Int. Unit Method

1. Erythropoiesis :: Increased hbA1c : Iron, Vitamin B12 deficiency, decreased erythropoietin.

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 7 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 8 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 9 of

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Limitations Of The Procedure :

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 10

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 11

:Ms. RENUKA BISWAS

Test Name Result Bio.Ref.Int. Unit Method

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 12

NAME :Ms. RENUKA BISWAS

Primary Sample Type : Urine

Routine Culture : Aerobic: No significant microorganism grown after 48 hours

*** End Of Report ***

Print DateTime: 13-11-2024 20:39:39 Printed By:KAUSIK SAHA Page 13

Patient Data Analysis Data

NGSP Retention Peak

Total Area: 2,409,426

HbA1c (NGSP) = 5.4 %

0.00 0.25 0.50 0.75 1.00 1.25 1.50

You might also like

* End Of Report *